Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Therma Bright Inc (TSV:THRM)

0.0550 UNCHANGED
Streaming Delayed Price Updated: 2:59 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Therma Bright Inc

< Previous 1 2 3 4 Next >
News headline image
Therma Bright Awaits FDA-EUA Approval From Over 260 AcuVid(TM) Clinical Study Test Results
Toronto, Ontario--(Newsfile Corp. - July 22, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its... 
Via Newsfile
News headline image
Therma Bright's AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Successfully Detects the COVID-19 Delta Variant Strain
Toronto, Ontario--(Newsfile Corp. - July 8, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its... 
Via Newsfile
News headline image
Therma Bright Secures US Distributor 'DME Authority' for Its Patented Venowave Lightweight Deep Vein Thrombosis (DVT) Device, Just as US Healthcare Providers Deal with Device Shortages
Toronto, Ontario--(Newsfile Corp. - June 28, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its... 
Via Newsfile
News headline image
Therma Bright to Test AcuVid(TM) on the Highly Contagious COVID-19 Delta Variant, Company Completes Brazilian Clinical Study for Final FDA EUA Submission
Toronto, Ontario--(Newsfile Corp. - June 24, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its... 
Via Newsfile
News headline image
Therma Bright Reports Performance of Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test from Brazilian Clinical Study
Toronto, Ontario--(Newsfile Corp. - June 17, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of the... 
Via Newsfile
News headline image
Therma Bright Provides Update on Brazilian Clinical Study
Toronto, Ontario--(Newsfile Corp. - May 27, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its... 
Via Newsfile
News headline image
Therma Bright Secures Development and Manufacturing Partner for AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
Toronto, Ontario--(Newsfile Corp. - May 21, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its... 
Via Newsfile
Topics Intellectual Property
News headline image
Therma Bright Enters into Agreement to Distribute a 15 Minute Rapid COVID-19 Antibody Test
Toronto, Ontario--(Newsfile Corp. - May 6, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of the... 
Via Newsfile
News headline image
Therma Bright Partners With Afero To Make AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Smart-Enabled
Toronto, Ontario--(Newsfile Corp. - April 28, 2021) - Afero has entered into a memorandum of understanding (MOU) agreement with Therma... 
Via Newsfile
Topics Intellectual Property
News headline image
Therma Bright's AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Detects the Important SARS-CoV-2 Variants of Concern; the Brazilian P.1 and P.2 and the UK B.1.1.7 Variants
Toronto, Ontario--(Newsfile Corp. - April 22, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of the... 
Via Newsfile
News headline image
Therma Bright Announces EU-CE Approval for AcuVid(TM) COVID-19 Rapid Antigen Saliva Test and Conditional Sale for 100,000 CE-only AcuVid(TM) Test Kits
Toronto, Ontario--(Newsfile Corp. - April 19, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of the... 
Via Newsfile
News headline image
Therma Bright Provides Update on Brazilian Performance Study of its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test
Toronto, Ontario--(Newsfile Corp. - April 13, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of the... 
Via Newsfile
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.